PRPH2 — peripherin 2

The PRPH2 gene provides the instructions for making a protein called peripherin-2, which is essential for normal vision. This protein is found exclusively in the retina, the light-sensitive tissue at the back of the eye. Specifically, peripherin-2 works in the photoreceptor cells (rods and cones), which are the cells that capture light. Inside these cells, peripherin-2 acts like a structural scaffold, helping to build and maintain the complex, stacked disc-like structures that house the light-sensing machinery. Without properly formed discs, the photoreceptor cells cannot function correctly and eventually die. When there is a mutation (a harmful change) in the PRPH2 gene, the peripherin-2 protein may be formed incorrectly or not produced in sufficient amounts. This disrupts the structure of the photoreceptor discs, leading to a gradual breakdown of the light-sensing cells. For patients, this manifests as an inherited retinal disease (IRD). The specific symptoms can vary widely, even among family members with the same mutation. Some people may develop a macular dystrophy, which primarily affects central vision and the ability to read or recognize faces, often starting in mid-to-late adulthood. Others may develop retinitis pigmentosa, which typically begins with night blindness and a gradual loss of peripheral (side) vision. Most PRPH2 mutations are inherited in an autosomal dominant pattern. This means that a person only needs one altered copy of the gene (inherited from either parent) to develop the condition. Consequently, an affected individual has a 50% chance of passing the mutated gene to each of their children. Because the severity and type of vision loss can be so unpredictable with PRPH2 mutations, genetic counseling is highly recommended for affected families to understand the risks, the nature of the condition, and the potential implications for future generations.

Gene description: Encodes a transmembrane glycoprotein that is a major structural component of the rim region of rod and cone photoreceptor outer segment disc membranes.

Patient and family guide: The PRPH2 gene provides the instructions for making a protein called peripherin-2, which is essential for normal vision. This protein is found exclusively in the retina, the light-sensitive tissue at the back of the eye. Specifically, peripherin-2 works in the photoreceptor cells (rods and cones), which are the cells that capture light. Inside these cells, peripherin-2 acts like a structural scaffold, helping to build and maintain the complex, stacked disc-like structures that house the light-sensing machinery. Without properly formed discs, the photoreceptor cells cannot function correctly and eventually die. When there is a mutation (a harmful change) in the PRPH2 gene, the peripherin-2 protein may be formed incorrectly or not produced in sufficient amounts. This disrupts the structure of the photoreceptor discs, leading to a gradual breakdown of the light-sensing cells. For patients, this manifests as an inherited retinal disease (IRD). The specific symptoms can vary widely, even among family members with the same mutation. Some people may develop a macular dystrophy, which primarily affects central vision and the ability to read or recognize faces, often starting in mid-to-late adulthood. Others may develop retinitis pigmentosa, which typically begins with night blindness and a gradual loss of peripheral (side) vision. Most PRPH2 mutations are inherited in an autosomal dominant pattern. This means that a person only needs one altered copy of the gene (inherited from either parent) to develop the condition. Consequently, an affected individual has a 50% chance of passing the mutated gene to each of their children. Because the severity and type of vision loss can be so unpredictable with PRPH2 mutations, genetic counseling is highly recommended for affected families to understand the risks, the nature of the condition, and the potential implications for future generations.

Gene function: PRPH2 is critical for the structural integrity and stability of photoreceptor outer segment discs, which are essential for phototransduction. It plays a role in disc morphogenesis and stacking. Mutations in PRPH2 lead to disruption of outer segment structure, impairing the ability of photoreceptors to detect light and transmit visual signals, resulting in progressive retinal degeneration and vision loss.

Protein structure: The PRPH2 gene encodes peripherin-2, a 346-amino acid integral membrane glycoprotein belonging to the tetraspanin family. The protein structure is characterized by four transmembrane domains (TM1-TM4) that anchor it to the photoreceptor disc membrane. It features two intracellular domains (the N-terminus and C-terminus) and two extracellular (intradiscal) loops: a small D1 loop and a large D2 loop. The large D2 loop is particularly critical for the protein's function, containing highly conserved cysteine residues that form essential intramolecular disulfide bonds necessary for proper folding and stability. Peripherin-2 does not function as a monomer; rather, it assembles into complex oligomeric structures. It first forms non-covalent homodimers or heterodimers with a related protein called ROM1. These dimers then assemble into larger tetramers and higher-order multimers (octamers and beyond) through intermolecular disulfide bonding mediated by specific cysteine residues within the D2 loop. This multimeric assembly is crucial for creating the structural network that maintains the flattened shape and highly curved rims of the photoreceptor outer segment discs. The protein also undergoes post-translational modifications, including N-linked glycosylation in the D2 loop, which is important for its stability and proper trafficking to the outer segment.

Molecular function: The PRPH2 gene encodes peripherin-2, a critical structural protein essential for the morphogenesis, stabilization, and maintenance of the light-sensitive outer segments of both rod and cone photoreceptors. The outer segment consists of a dense stack of flattened membranous discs packed with visual pigments (like rhodopsin). Peripherin-2 is specifically localized to the highly curved rim regions of these discs, where it acts as a structural scaffold. It functions by inducing and stabilizing the extreme membrane curvature required to form the flattened disc structure from the ciliary plasma membrane. At the molecular level, peripherin-2 functions as an adhesion molecule that holds the opposing membranes of the disc rim together. It achieves this through complex intermolecular interactions. Peripherin-2 forms homodimers and also heterodimers with a closely related tetraspanin protein called ROM1 (retinal outer medullary margin protein 1). These dimers further assemble into larger oligomeric complexes (tetramers and higher-order multimers) mediated by intermolecular disulfide bonds in the large intradiscal D2 loop. These oligomeric complexes form a continuous structural network along the disc rim, providing the necessary mechanical stability to withstand the continuous renewal process of the outer segment. Beyond its structural role, peripherin-2 is also implicated in the dynamic process of disc shedding and renewal. It interacts with other key outer segment proteins, including the cyclic nucleotide-gated (CNG) channel complex and melanoregulin, suggesting it may also play a role in organizing functional microdomains within the outer segment membrane and participating in the regulation of phototransduction or membrane trafficking pathways.

Expression pattern: The PRPH2 gene exhibits a highly specific and restricted expression pattern, being transcribed almost exclusively in the retina. Within the retina, PRPH2 expression is localized to the photoreceptor cells, specifically both rod and cone photoreceptors. The protein is synthesized in the inner segment of the photoreceptors and then transported to the outer segment, where it is concentrated at the rim regions of the membranous discs. Developmentally, PRPH2 expression begins during the later stages of photoreceptor differentiation, coinciding with the initiation of outer segment formation. Its expression is maintained throughout adulthood, reflecting its ongoing requirement for the continuous renewal and structural maintenance of the photoreceptor outer segment discs. There are no known tissue-specific isoforms outside of the retina, underscoring its specialized role in visual function.

Mutation spectrum: The mutation spectrum of the PRPH2 gene is diverse, with over 200 pathogenic variants identified to date. These include missense, nonsense, frameshift, and splice-site mutations, as well as small insertions and deletions. Missense mutations are the most common type and are distributed throughout the gene, but there is a notable concentration of pathogenic variants within the large intradiscal D2 loop, which is critical for protein folding, oligomerization, and interaction with ROM1. While there are no single predominant hotspot mutations that account for the majority of cases, certain variants are seen more frequently. For instance, the c.828+3A>T splice site mutation is a well-known founder mutation in certain populations and is a frequent cause of inherited retinal dystrophies. Other recurrent mutations include p.Arg172Trp and p.Arg172Gln. The vast majority of PRPH2 mutations are inherited in an autosomal dominant manner, causing disease through either haploinsufficiency (where half the normal amount of protein is not enough) or a dominant-negative mechanism (where the mutant protein interferes with the function of the normal protein). Biallelic mutations are rare but have been reported.

Pathogenic variants: 1. p.Arg172Trp (c.514C>T) - A highly recurrent missense mutation located in the D2 loop, frequently associated with central areolar choroidal dystrophy (CACD) and various pattern macular dystrophies, exhibiting significant variable expressivity. 2. c.828+3A>T - A common splice-site founder mutation that leads to aberrant splicing and typically results in haploinsufficiency. It is associated with a wide range of phenotypes, from asymptomatic carriers to severe retinitis pigmentosa. 3. p.Arg172Gln (c.515G>A) - Another common missense mutation at the same codon as Arg172Trp, also primarily associated with macular dystrophies and CACD. 4. p.Pro210Arg (c.629C>G) - A missense mutation in the D2 loop often associated with retinitis pigmentosa (RP7) and severe, progressive visual field loss. 5. p.Gly167Asp (c.500G>A) - A missense variant that disrupts a conserved residue in the D2 loop, known to cause pattern dystrophy and occasionally more widespread retinal degeneration.

Clinical significance: Mutations in the PRPH2 gene are associated with a remarkably broad and highly variable spectrum of inherited retinal diseases (IRDs). The clinical manifestations can be broadly categorized into macular dystrophies and widespread retinal dystrophies. The most common presentations include pattern macular dystrophies (such as adult-onset vitelliform macular dystrophy and butterfly-shaped pigment dystrophy), central areolar choroidal dystrophy (CACD), retinitis pigmentosa (RP7), and cone-rod dystrophy. The severity and age of onset vary significantly depending on the specific mutation and even among individuals with the same mutation within a single family, indicating variable expressivity and incomplete penetrance. Pattern dystrophies typically present in adulthood (often in the 4th to 6th decades of life) with mild to moderate central vision loss, metamorphopsia, and characteristic pigmentary changes in the macula. In contrast, PRPH2-associated retinitis pigmentosa often presents earlier with nyctalopia (night blindness) and progressive peripheral visual field loss, eventually leading to severe visual impairment. Biallelic (homozygous or compound heterozygous) mutations in PRPH2 are rare but can cause a severe, early-onset retinal dystrophy resembling Leber congenital amaurosis (LCA). Systemic features are generally absent, as PRPH2 expression is highly restricted to the retina.

Inheritance: Autosomal Dominant

Chromosomal location: 6p21.1

Genotype-phenotype correlations: Genotype-phenotype correlations in PRPH2-associated diseases are notoriously complex and often unpredictable. While certain mutations are more frequently associated with specific clinical diagnoses, there is significant overlap. For example, mutations in the large intradiscal D2 loop (such as p.Arg172Trp) are often associated with macular dystrophies, while mutations in the transmembrane domains or the C-terminus may be more frequently linked to retinitis pigmentosa. However, the same specific mutation (e.g., p.Arg172Trp or the c.828+3A>T splice site variant) can cause pattern dystrophy in one family member, retinitis pigmentosa in another, and remain asymptomatic in a third, highlighting profound variable expressivity. This phenotypic variability suggests that other genetic modifiers, environmental factors, or epigenetic influences play a significant role in determining the final clinical outcome. Generally, nonsense, frameshift, and splice-site mutations that lead to haploinsufficiency tend to cause milder, later-onset phenotypes like pattern dystrophies, whereas missense mutations that exert a dominant-negative effect by interfering with the assembly of wild-type PRPH2 or ROM1 often result in more severe, earlier-onset widespread retinal degenerations like retinitis pigmentosa. Biallelic mutations consistently result in severe, early-onset retinal dystrophy.

Research and therapeutic approaches: Currently, there are no FDA-approved targeted therapies or cures for PRPH2-associated retinal diseases. Clinical management primarily focuses on supportive care, including low vision aids, regular monitoring for complications like choroidal neovascularization (which can be treated with anti-VEGF injections), and genetic counseling. The variable expressivity and the fact that most mutations act via a dominant-negative mechanism or haploinsufficiency make developing a universal therapy challenging. However, several therapeutic strategies are in the preclinical pipeline. Gene augmentation therapy, which has been successful for recessive conditions like RPE65-associated LCA (Luxturna), is being explored for PRPH2 haploinsufficiency models. Studies in rds mice have shown that delivering a functional copy of the PRPH2 gene via adeno-associated virus (AAV) vectors or compacted DNA nanoparticles can improve outer segment structure and preserve visual function. For dominant-negative mutations, more complex approaches are required, such as "knockdown and replace" strategies, where the mutant allele is silenced (e.g., using RNA interference or antisense oligonucleotides) while simultaneously providing a functional wild-type gene. Other investigational approaches include CRISPR/Cas9 gene editing to directly correct specific mutations, and neuroprotective strategies aimed at slowing photoreceptor degeneration regardless of the underlying genetic defect. Recent preclinical studies have also suggested that downregulating rhodopsin levels might be an effective strategy to alleviate the structural burden on the outer segment and preserve photoreceptors in the context of PRPH2 mutations. While these approaches show promise in animal models, significant optimization is needed before they can advance to human clinical trials.

Diagnostic testing: Diagnostic testing for PRPH2-associated retinal diseases typically involves molecular genetic testing, most commonly through targeted next-generation sequencing (NGS) panels that include PRPH2 along with other known IRD genes. Whole exome sequencing (WES) or whole genome sequencing (WGS) may also be utilized, particularly when panel testing is uninformative or when a broader genetic assessment is desired. Clinical evaluation, including fundus examination, optical coherence tomography (OCT), fundus autofluorescence (FAF), and electroretinography (ERG), is essential to characterize the specific phenotype and guide genetic testing. Genetic counseling is a critical component of the diagnostic process. Since most PRPH2 mutations are inherited in an autosomal dominant manner, affected individuals have a 50% chance of passing the pathogenic variant to each of their children. However, due to the high degree of variable expressivity and incomplete penetrance associated with PRPH2 mutations, predicting the exact clinical presentation, age of onset, and severity of the disease in offspring can be challenging. De novo mutations also occur, meaning a patient may be the first in their family to have the condition. Biallelic mutations, inherited in an autosomal recessive pattern, are rare but require specific counseling regarding carrier status and recurrence risks.

Animal models: The most extensively used animal model for studying PRPH2 is the rds (retinal degeneration slow) mouse, which carries a spontaneous mutation in the Prph2 gene. Homozygous rds mice (Prph2-/-) completely fail to develop photoreceptor outer segments, leading to slow but progressive apoptotic death of both rod and cone photoreceptors. Heterozygous rds mice (Prph2+/-) develop abnormal, shortened outer segments with whorl-like membranous structures instead of properly stacked discs, and exhibit a slower rate of retinal degeneration. These models have been instrumental in demonstrating that PRPH2 is absolutely essential for the morphogenesis and structural maintenance of photoreceptor outer segment discs. In addition to the classic rds mouse, several knock-in mouse models have been generated to study specific human pathogenic variants, such as the R172W and Y141C mutations. These models have revealed that different PRPH2 mutations can cause distinct disease mechanisms, including dominant-negative effects where the mutant protein interferes with the function of the wild-type protein, or haploinsufficiency where a 50% reduction in functional protein is insufficient for normal outer segment maintenance. Zebrafish models have also been utilized to study the developmental role of PRPH2 orthologs in photoreceptor genesis and visual function.

Population genetics: The overall carrier frequency of pathogenic PRPH2 variants in the general population is relatively low, but PRPH2 is considered one of the more commonly mutated genes among individuals with autosomal dominant inherited retinal diseases, accounting for approximately 3% to 5% of such cases. Analysis of large population databases like gnomAD suggests a sum carrier frequency for known pathogenic or likely pathogenic ClinVar variants of approximately 1 in 3,758 individuals. Certain mutations exhibit founder effects in specific populations; for example, the c.828+3A>T splice site mutation is particularly prevalent in some European cohorts. The high degree of incomplete penetrance associated with some PRPH2 variants means that a portion of individuals carrying a pathogenic mutation may remain asymptomatic throughout their lives, complicating precise prevalence estimates.

Selected references: 1. AlAshwal SM, et al. PRPH2-Associated Retinal Diseases. Am J Ophthalmol, 2025. PMID: 38762345 2. Bianco L, et al. PRPH2-Associated Retinopathy. Ophthalmol Retina, 2023. PMID: 36805432 3. Coco-Martin RM, et al. PRPH2-Related Retinal Diseases: Broadening the Clinical Spectrum. Genes (Basel), 2020. PMID: 32664405 4. Chakraborty D, et al. Novel molecular mechanisms for Prph2-associated pattern dystrophy. FASEB J, 2020. PMID: 32031725 5. Peeters MHCA, et al. PRPH2 mutation update: In silico assessment of 245 reported variants. Hum Mutat, 2021. PMID: 33484055 6. Conley SM, et al. Gene Therapy for PRPH2-Associated Ocular Disease. Cold Spring Harb Perspect Med, 2014. PMID: 25368015 7. Ayyagari R, et al. Current and Future Directions in Developing Effective Therapies for PRPH2-Associated Retinopathies: A Workshop Report. Transl Vis Sci Technol, 2024. PMID: 38451525